18 December 2024NewsAmericasRajiv Nayar President HTD Biosystems, Chuck Sholtz Vice President Intellectual Property Nutcracker Therapeutics, Benjamin Pelletier Partner Haynes & Boone

WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

The patent landscape for biologics, biosimilars, and advanced therapeutic antibodies is undergoing rapid change, presenting both opportunities and challenges for innovators and manufacturers. This panel will explore current issues and strategies in this dynamic field.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Patent cliff: 5 blockbusters running out of road

Herbert Smith Freehills expands German tech patent team

‘Always new twists’: Bayer legal team on defending a $4bn drug

Novartis and MSN feud intensifies after Fed Circ denies rehearing

EU court signals tough stance on ‘pay-for-delay’ pharma deals

Panitch Schwarze hires experienced ex-USPTO examiner

Fed Circ affirms generic’s litigation costs of $12m are tax-deductible

Genmab fights claim over 'secrets theft' behind $1.8bn takeover

WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

Editor's picks

Editor's picks

More features